Investing.com - Financial Markets Worldwide
🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

TRACON Pharmaceuticals Inc (TCON)

OTC Markets
Currency in USD
0.0322
-0.0113(-22.99%)
Closed
TCON Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Unlock Value
Day's Range
0.03220.0468
52 wk Range
0.002014.7460
Key Statistics
Edit
Prev. Close
0.0435
Open
0.04
Day's Range
0.0322-0.0468
52 wk Range
0.002-14.746
Volume
23.89K
Average Vol. (3m)
19.93K
1-Year Change
-99.14%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TCON Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Technical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
pro lock
Unlock All 14
Analysts anticipate sales decline in the current year
Unlock InvestingPro

TRACON Pharmaceuticals Inc News & Analysis

Show more

TRACON Pharmaceuticals Inc Company Profile

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company’s clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Industry
Pharmaceuticals
Sector
Healthcare
Employees
17
Market
United States

Compare TCON to Peers and Sector

Metrics to compare
TCON
Peers
Sector
Relationship
P/E Ratio
0.0x−2.5x−0.7x
PEG Ratio
0.00−0.050.00
Price / Book
0.0x2.1x2.6x
Price / LTM Sales
0.0x10.0x3.2x
Upside (Analyst Target)
-172.0%47.0%
Fair Value Upside
Unlock16.6%7.5%Unlock

FAQ

What Is the TRACON Pharma (TCON) Stock Price Today?

The TRACON Pharma stock price today is 0.0322

What Stock Exchange Does TRACON Pharma Trade On?

TRACON Pharma is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for TRACON Pharma?

The stock symbol for TRACON Pharma is "TCON."

What Is the TRACON Pharma Market Cap?

As of today, TRACON Pharma market cap is 109.72K.

What is TRACON Pharma Earnings Per Share?

The TRACON Pharma EPS is 2.29.

From a Technical Analysis Perspective, Is TCON a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.